NYBSP-4
A chemically modified peptide targeting SARS-CoV-2 Spike protein.
General information
NYBSP-4 is a hydrocarbon-stapled peptide derived from an hACE2 α-helical region (Curreli et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In Vitro
Biophysical assay Peptide In vitro |
in vitro biophysical assay; HT1080/ACE2 cells; A549/ACE2 cells; Vero E6 cells; Sars-CoV-2 pseudovirus single-cycle assay; authentic SARS-CoV-2 strain US_WA-1/2020 | 6.78 | Bound SARS-CoV-2 Spike RBD in vitro with binding constant of 2.2 μM. Inhibited SARS-CoV-2 pseudovirus in a single-cycle assay with IC50 of ca. 1.97 μM and 2.8 μM in HT1080/ACE2 and A549/ACE2 cells, respectively. The peptide was stable in human plasma ex vivo. Completely blocked SARS-CoV-2-induced cytopathic effect in Vero E6 cells at ca. 33 μM. |
Dec/11/2020 |
AI-suggested references
| Link | Publication date |
|---|---|
|
Targeting SARS-CoV-2 Receptor Binding Domain with Stapled Peptides: An In Silico Study
|
Jun/11/2021 |
